Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
The clone designated HL-60/MX2 was approximately 35 fold less sensitive to mitoxantrone than the HL-60 parental cells.
HL-60/MX2 cells display atypical multidrug resistance (MDR) with the absence of P-glycoprotein overexpression and altered topoisomerase II catalytic activity and reduced levels of topoisomerase II alpha and beta proteins.
HL-60/MX2 cells are cross-resistant to etoposide, teniposide, bisantrene, dactinomycin, 4'-(9-acridinylamino)methane- sulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloids vincristine and vinblastine, melphalan, mitomycin C and cisplatin.
Resistance to mitoxantrone is stable for up to six months.
Harker WG, et al. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49: 4542-4549, 1989. PubMed: 2568172
Harker WG, et al. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30: 9953-9961, 1991. PubMed: 1655025
